Search
for
Sort by
Research 30 of 416
- Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
- Melanotic pigmentation in excisional scar of melanoma patient who received BRAF and MEK inhibitors
- 422 Human hair follicles express PD-L1, whose expression is down-regulated by EGFR and MEK inhibitors ex vivo. A potential mechanism for EGFR inhibitor induced sterile folliculitis
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- 645 MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Cutaneous toxicities of new treatments for melanoma
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- When bugs and drugs conspire: driving acneiform skin toxicity
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- 642 Uncovering the role of UV exposure history and genetics in determining skin sun damage
- Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Dihydrotestosterone Induces Keratinocyte Apoptosis by Activating ERK Signaling
- Sorafenib-induced eruption resembling pityriasis rubra pilaris
- Cutaneous adverse effects of targeted therapies
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Progesterone promotes the survival of newborn neurons in the dentate gyrus of adult male mice
- Management of Dermatologic Toxicities
- Progesterone Promotes the Survival of Newborn Neurons in the Dentate Gyrus of Adult Male Mice
- RASopathic Skin Eruptions during Vemurafenib Therapy
- Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies